StockData
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$2.83−11.27 (-79.93%)

Close on Nov 17, 2026Market cap $20.56MP/E –Yield –

Cue Biopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cue Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$50.05M. For fiscal 2025 it was -$21.69M. The highest annual figure on record is -$12.14M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$21.69M–
FY2024Dec 31, 2024-$36.33M–
FY2023Dec 31, 2023-$39.96M–
FY2022Dec 31, 2022-$41.81M–
FY2021Dec 31, 2021-$38.84M–
FY2020Dec 31, 2020-$32.49M–
FY2019Dec 31, 2019-$30.80M–
FY2018Dec 31, 2018-$26.41M–
FY2017Dec 31, 2017-$12.14M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.00M–
Q1 FY2026Mar 31, 2026-$10.94M–
Q4 FY2025Dec 31, 2025-$1.08M–
Q3 FY2025Sep 30, 2025-$9.02M–
Q2 FY2025Jun 30, 2025-$3.42M–
Q1 FY2025Mar 31, 2025-$8.17M–
Q4 FY2024Dec 31, 2024-$9.03M–
Q3 FY2024Sep 30, 2024-$7.53M–
Q2 FY2024Jun 30, 2024-$9.99M–
Q1 FY2024Mar 31, 2024-$9.78M–
Q4 FY2023Dec 31, 2023-$10.96M–
Q3 FY2023Sep 30, 2023-$7.80M–
Q2 FY2023Jun 30, 2023-$10.37M–
Q1 FY2023Mar 31, 2023-$10.83M–
Q4 FY2022Dec 31, 2022-$10.51M–
Q3 FY2022Sep 30, 2022-$6.87M–
Q2 FY2022Jun 30, 2022-$12.85M–
Q1 FY2022Mar 31, 2022-$11.57M–
Q4 FY2021Dec 31, 2021-$10.65M–
Q3 FY2021Sep 30, 2021-$6.63M–
Q2 FY2021Jun 30, 2021-$9.77M–
Q1 FY2021Mar 31, 2021-$11.80M–
Q4 FY2020Dec 31, 2020-$7.00M–
Q3 FY2020Sep 30, 2020-$7.69M–
Q2 FY2020Jun 30, 2020-$6.86M–
Q1 FY2020Mar 31, 2020-$10.94M–
Q4 FY2019Dec 31, 2019-$6.44M–
Q3 FY2019Sep 30, 2019-$9.21M–
Q2 FY2019Jun 30, 2019-$6.68M–
Q1 FY2019Mar 31, 2019-$8.48M–
Q4 FY2018Dec 31, 2018-$3.90M–
Q3 FY2018Sep 30, 2018-$6.30M–
Q2 FY2018Jun 30, 2018-$6.46M–
Q1 FY2018Mar 31, 2018-$9.76M–
Q4 FY2017Dec 31, 2017-$1.85M–
Q3 FY2017Sep 30, 2017-$3.68M–
Q2 FY2017Jun 30, 2017-$3.16M–
Q1 FY2017Mar 31, 2017-$3.46M–

More Cue Biopharma figures

See a number that looks wrong?